Assenagon Asset Management S.A. Lowers Stake in DexCom, Inc. (NASDAQ:DXCM)

Assenagon Asset Management S.A. lessened its holdings in DexCom, Inc. (NASDAQ:DXCM) by 34.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 646,846 shares of the medical device company’s stock after selling 342,894 shares during the period. Assenagon Asset Management S.A. owned about 0.17% of DexCom worth $50,305,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds also recently bought and sold shares of the company. Allen Mooney & Barnes Investment Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $477,000. Cardinal Point Capital Management ULC purchased a new stake in DexCom in the 4th quarter worth $249,000. 180 Wealth Advisors LLC acquired a new position in DexCom during the fourth quarter worth $255,000. Cullen Investment Group LTD. lifted its holdings in DexCom by 5.6% during the fourth quarter. Cullen Investment Group LTD. now owns 11,502 shares of the medical device company’s stock valued at $895,000 after purchasing an additional 614 shares in the last quarter. Finally, CHICAGO TRUST Co NA grew its position in shares of DexCom by 67.9% in the fourth quarter. CHICAGO TRUST Co NA now owns 18,236 shares of the medical device company’s stock valued at $1,418,000 after purchasing an additional 7,373 shares during the period. Hedge funds and other institutional investors own 97.75% of the company’s stock.

DexCom Stock Up 1.6 %

DXCM stock opened at $80.40 on Thursday. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The firm has a market cap of $31.40 billion, a PE ratio of 48.14, a PEG ratio of 2.36 and a beta of 1.12. The firm’s 50 day moving average price is $77.57 and its 200-day moving average price is $78.37. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Raymond James decreased their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Finally, Leerink Partners dropped their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and an average price target of $98.00.

Insider Buying and Selling at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the completion of the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.